This is a routine annual meeting governance filing with no financial data, guidance, or operational catalysts. The additional share authorizations enable future equity grants and ESPP purchases but represent no immediate dilution. Neither the COCH common nor COCHW warrants have a trading catalyst here. Monitor future 8-Ks for actual equity grants that could signal dilution.
Price Chart
Executive Summary
Envoy Medical reported results from its 2026 Annual Meeting held May 12, 2026. Stockholders approved amendments to the 2023 Equity Incentive Plan and Employee Stock Purchase Plan, authorizing an additional 6,000,000 and 1,200,000 shares of Class A Common Stock, respectively, for issuance. The filing also covers the re-election of two Class III directors, ratification of the auditor, and ratification of prior warrant issuances — all routine governance items with no material financial data.
Key Facts
- Stockholders approved an additional 6,000,000 shares of Class A Common Stock for the 2023 Equity Incentive Plan, bringing the total share reserve to 10,000,000 shares.
- Stockholders approved an additional 1,200,000 shares of Class A Common Stock for the 2023 Employee Stock Purchase Plan, bringing the total available to 4,300,000 shares.
- Two Class III directors (Brent T. Lucas and Susan J. Kantor) were re-elected to the Board through 2029.
- EisnerAmper, LLP was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026.
- Stockholders approved, on a non-binding advisory basis, named executive officer compensation.
- Stockholders approved the issuance of warrants (and underlying shares) that were issued in a transaction completed on February 12, 2026, for Nasdaq Listing Rule 5635(d) compliance.
Financial Impact
No financial figures were reported. The share authorizations are enabling resolutions — no shares were issued, priced, or sold in this filing.
Risk Factors
- The additional 6,000,000 shares authorized under the equity plan represent potential future dilution if shares are granted and vested.
- The additional 1,200,000 shares for the ESPP represent potential future dilution through employee stock purchases.
- No operational or financial performance updates were provided to assess the company's trajectory.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-058429 |
| Document: ea029135401ex10-1.htm | 0001213900-26-058429 |
| Document: ea029135401ex10-2.htm | 0001213900-26-058429 |
| Document: 0001213900-26-058429-index-headers.html | 0001213900-26-058429 |
| Document: 0001213900-26-058429-index.html | 0001213900-26-058429 |
| Document: 0001213900-26-058429.txt | 0001213900-26-058429 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 23w ago | 8-K | $0.0475 $0.0325 | ▼ −31.58% | ▼ −32.56% | — |
May 11, 2026 24w ago | 8-K | $0.0475 $0.0475 | · 0.00% | ▲ +0.30% | — |
Apr 17, 2026 27w ago | 3 | $0.0475 $0.0475 | · 0.00% | ▼ −4.20% | — |
Apr 13, 2026 28w ago | 10-K/A | $0.0475 $0.0475 | · 0.00% | ▼ −6.30% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers